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Abstract
Obesity confers an increased risk for cardiovascular renal diseases, diabetes mellitus,
nonalcoholic steatohepatitis, musculoskeletal disorders, and cancers. Prokineticin‐Ř is
a peptide hormone, which exists as both a circulating hormone system and a local
paracrine‐signaling mechanism within various tissues including the brain, kidney, and
adipose. It acts on the G‐protein‐coupled receptors (GPCRs) PKRŗ and PKRŘ. The role
of  prokineticin‐Ř  in  the  central  nervous  system  is  the  control  of  food  intake.  Its
anorexigenic efect is at least partly through the hypothalamic melanocortin system.
Prokineticin‐Ř  also  prevents  adipose  tissue  expansion  by  limiting  preadipocyte
proliferation  and  diferentiation  capacity.  Prokineticin‐Ř  signaling  is  important  for
insulin capillary passages. It also regulates heart and kidney development and function.
Here, we discuss a new obesity peptide prokineticin signaling in central regulation of
food intake, adipocyte tissue development, and cardiovascular function. Prokineticin
may play a key role in the association between obesity and cardiovascular diseases. We
also outline the potential of prokineticin receptor‐ŗ as target for the treatment of obesity
and cardiovascular diseases.
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ŗ. Introduction
Obesity is a major health problem and an increased risk factor that worsens cardiovascular
events leading to higher morbidity and mortality. [ŗ] Several cardiovascular diseases can also
occur due to structural and functional changes of the myocardium through excess fat deposition
and other mechanisms related to obesity [Ř]. However, the mechanisms of relation between
obesity and cardiovascular events are unclear. Nevertheless, pharmacological therapy for
obesity has great potential to improve cardiovascular problems. Several anorexcigenic peptides
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have been studied as potential drugs in the treatment of obesity [ř]. Recent evidence showed
that some brain regions may not only be involved in food intake regulation but also play an
important role in the regulation of cardiovascular blood homeostasis [Ś]. The rising prevalence
of both obesity and heart failure make this association an important target for prevention.
Therefore, it is important to determine the common mechanisms regulating both obesity and
cardiovascular events. Identiication of signaling pathways linking obesity and cardiovascular
disease is important for the development of novel therapeutics. Here, we summarize the current
information on the role of anorexigenic peptide prokineticin in obesity and cardiovascular renal
diseases, emphasizing prokineticin receptor‐ŗ signaling in these events.
Ř. Prokineticins and their receptors
Prokineticins are anorexigenic and angiogenic hormones. ”ecause of the structural, signaling
and functional similarities, prokineticins are considered as cytokines/chemokines [ś]. They are
released principally by macrophages and reproductive organs [Ŝ]. Recently, prokineticin is
considered as an adipokine because a high level of prokineticins has been found in obese
human W“T [ŝ]. These small peptides (ŞŖ–ŗŘŖ amino acids) are called prokineticins, because
these molecules were irst identiied as potent contractile factors in the gastrointestinal tract
[Ş]. Two isoforms of prokineticins have been identiied: prokineticin‐ŗ and prokineticin‐Ř.
Prokineticin‐ŗ has been originally called as endocrine gland‐derived vascular endothelial
growth factor (EG‐VEGF), [ş] because of its functional similarity to VEGF. Prokineticin‐Ř is
also called as ”vŞ. ”oth of these peptides are Śś% identical with highly conserved N‐terminal
“VITG“ motif essential for their biological activity [Ŝ, ŗŖ]. Prokineticin activity is mediated
by two G‐protein‐coupled receptors, PKRŗ and PKRŘ [ŗŗ].
Ř.ŗ. Prokineticin‐Ř is an anorexigenic peptide
Circulating hormones and nutrients are integrated to mediate the regulation of short‐term and
long‐term dietary intakes in the hypothalamus. “ feeding and energy homeostasis control
center in the hypothalamus is called as arcuate nucleus (“RC) [ŗŘ, ŗř]. The “RC integrates
most of the peripheral hormonal signals including leptin, insulin and ghrelin. The “RC has
two major subpopulations of primary neurons that express neurohormones with opposing
efects on food intake. “RC neurons that release the proopiomelanocortin (POMC)‐derived
peptide alpha‐melanocyte‐stimulating hormone (α‐MSH) and cocaine‐ and amphetamine‐
regulated transcript (C“RT) peptide potently reduce food intake [ŗř, ŗŚ]. However, neuro‐
peptide Y (NPY)‐producing neurons in the “RC stimulate food intake.
Prokineticin‐Ř is involved in the control of food intake and of fat mass through actions in the
“RC in the hypothalamus [ŗś]. PKRŗ receptor is expressed on both NPY/“gRP and POMC/
C“RT neurons. Intracranial injection of prokineticin‐Ř in rats strongly decreases food intake.
Controversy, anti‐prokineticin‐Ř antibody increases food intake. “norexigenic efect of pro‐
kineticin‐Ř is mediated at least partly via the hypothalamic “RC melanocortin system. Proki‐
neticin‐Ř increases the release of alpha‐MSH from ex vivo hypothalamic explants. Recently,
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PKRŗ has been shown as the irst non‐melanocortin GPCR to be regulated by the melanocor‐
tin receptor accessory protein Ř (MR“PŘ). Indeed, MR“PŘ signiicantly and speciically in‐
hibits PKRŗ signaling [ŗŜ].
Peripheral administration of prokineticin‐Ř reduces food intake and body weight in both
lean mice and diet‐induced obesity models [ŗŝ]. This efect of prokineticin‐Ř is not evident
when appetite is increased or feeding behavior is promoted. Hypothalamic prokineticin‐Ř
levels were found extremely high in the early neonatal period. However, a decreased level of
prokineticin‐Ř was evident under fasting conditions [ŗŞ]. Prokineticin‐Ř‐knockout mice be‐
came obese at the late age. Humans with the inactivating mutations of prokineticin‐Ř gene
are also obese [ŗŝ, ŗş]. The anorectic efects of prokineticin‐Ř are abolished by PKRŗ antago‐
nists and not observed in mice lacking PKRŗ [ŗŝ]. Thus, the anorectic efects of prokineticin‐
Ř in the hypothalamus are mediated by PKRŗ.
Ř.Ř. Prokineticin in the development of obesity
The mechanisms underlying the development of obesity include the hypertrophy and/or
hyperplasia of adipocytes, adipose tissue (“T) inlammation, impaired extracellular matrix
remodeling and ibrosis together with an altered secretion of adipokines [ŘŖ]. “T expansion
involves two distinct mechanisms: an enlargement in adipose cells and an increase of adipo‐
cytes number [Řŗ]. Diferentiated adipocytes are post‐mitotic and therefore hyperplasia is the
result of increased de novo adipocyte formation (adipogenesis). Impaired adipogenesis is
associated with insulin resistance [ŘŘ]. The balance between proliferation and diferentiation
of preadipocytes and adipocyte apoptosis or necrosis determines adipocyte number.
Prokineticin‐Ř levels were found to be high in obese human W“T [ŝ]. Prokineticin‐Ř suppresses
“T expansion by two distinct mechanisms: the central regulation of food intake and limiting
preadipocyte proliferation and diferentiation. The central regulation of body weight is
counteracted by loss of PKRŗ in adipose tissue in mice. Indeed, an abnormally excessive
abdominal fat mass accumulation was observed in these mice where the PKRŗ speciically
deleted in the adipocytes (PKRŗad‐/‐) [ŝ]. The formation of new adipocytes in both PKRŗ null
and PKRŗad‐/‐ mice was resulted from an acceleration of preadipocyte proliferation and
diferentiation. “T proliferative phenotype has switch to “T hypertrophic phenotype when
these mice were treated with a high‐fat diet, implicating high calorie intake is involved in the
conversion of hyperplasia to hypertrophy. In isolated preadipocytes, PKRŗ activation sup‐
presses proliferation and adipogenic diferentiation [řŞ].
”oth PKRŗnull and PKRŗad‐/‐ mice display abdominal obesity [ŝ] However, only PKRŗnull mice
have peripheral obesity with a diabetes‐like syndrome. Thus, non‐adipocyte PKRŗ‐mediated
events contribute to the development of a diabetes‐like syndrome. Indeed, endothelial‐speciic
PKRŗ‐knockout mice (PKRŗec‐/‐) [Řř] had insulin resistance in adipocytes. In PKRŗec‐/‐ adipo‐
cytes, insulin cannot promote normal fat storage, resulting in excess circulating free faty acids
that, in turn, further contribute into insulin resistance in muscle, leading to diabetes‐like
syndrome. However, it seems that PKRŗ has no direct efect on fat deposition in adipocytes.
PKRŗad‐/‐ mice did not have severe accumulation of fat tissue in their adipocytes. Since
adipocytes are not created from other adipocytes, but they arise from precursor cells (preadi‐
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pocytes), PKRŗ suppress the ability of these precursor cells to become adipocytes (Figure ŗ)
[ŝ]. The expansion and metabolism of the adipose tissue are the major problem in obesity.
Figure ŗ. Prokineticin‐Ř/PKRŗ signaling may act as a new connector between development of obesity, diabetes and car‐
diovascular diseases. Prokineticin‐Ř/PKRŗ signaling in central nervous system (CNS) regulates food intake. Prokineti‐
cin‐Ř released from adipocytes controls preadipocyte conversion to adipocyte via PKRŗ signaling. Prokineticin‐Ř/PKRŗ
signaling promotes survival of cardiomyocytes and angiogenesis and involved in neovascularization by activating car‐
diac progenitor cells. Prokineticin‐Ř/PKRŗ signaling contributes to heart and kidney development as well as kidney
function. Whether this signaling involves heart and kidney regulation through CNS remains to be studied.
Ř.ř. Prokineticin in insulin resistance
The endothelium is essential for insulin transcapillary delivery to the skeletal muscle interstiti‐
um. This process is the rate‐limiting step in insulin‐stimulated glucose uptake. [ŘŚ] The impair‐
ment of insulin delivery process contributes to insulin resistance [Řś]. On the other hand, insulin
resistance leads to endothelial dysfunction [ŘŜ]. Thus, the vascular endothelium is a potential
therapeutic target for the prevention of insulin resistance and related complications [Řŝ].
Endothelium‐speciic PKRŗ‐knockout mice (PKRŗec‐/‐) display impaired capillary formation
and low transcapillary insulin uptake [Řř]. Impaired insulin delivery and signaling in endo‐
thelial cells (ECs) has been observed in cases of insulin resistance with type Ř diabetes and
obesity. Endothelial cells overexpressing PKRŗ promotes insulin transendothelial uptake [ş]
and angiogenesis [ŘŞ]. PKRŗec‐/‐ mice display lipodystrophy due to poor capillary formation in
the “T. Lipodystrophies, involving a loss of W“T, cause hyperphagia and peripheral insulin
resistance [Řş].
“s a summary, prokineticin regulates appetite (efects in central nervous system (CNS)) and
suppresses adipocyte expansion (direct efect on adipocyte tissue), promotes normal fat stor‐
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age (endothelial‐dependent efect) and increases insulin sensitivity. Therapeutic strategies
targeting PKRŗ could be important to treat obesity and obesity‐associated insulin resistance.
Ř.Ś. Prokineticin in cardiovascular regulation
Obesity is both an independent risk factor and a risk marker for the development of asymp‐
tomatic and symptomatic coronary artery disease, heart failure and atrial ibrillation [Ř]. The
relationship between obesity and cardiovascular diseases may be associated with hemody‐
namic and anatomic cardiovascular changes related to excess body mass [řŖ]. However, the
relationship can also be mediated by obesity‐related metabolic, inlammatory and neurohor‐
monal changes.
“ltered expression of prokineticins and their receptors has been implicated in the development
of a number of pathological cardiac conditions, including heart failure [řŗ]. Prokineticins and
their receptors have been identiied as an important cardiovascular‐signaling system especially
cardiac cell commitment and cell‐to‐cell communications [řŘ].
PKRŗ‐mediated signaling contributes to cardiomyocyte survival and adult heart repair. PKRŗ
activates “kt in cardiomyocyte to protect these cells against hypoxia‐mediated apoptosis [řř].
Transgenic (TG) mice‐overexpressing PKRŗ in the cardiomyocytes (TG‐PKRŗ) had an in‐
creased number of epicardial‐derived progenitor cells (EPDCs), with an increase of capillary
density and coronary arterioles. [řŘ] The cardiac‐PKRŗ signaling up‐regulates its own ligand
prokineticin‐Ř to stimulate the EPDC diferentiation into endothelial and smooth muscle cells
to promote neovasculogenesis [řŘ]. However, cardiomyocyte‐PKRŗ is essential for cardio‐
myocyte survival and contractility. PKRŗnull mice displayed cardiomyocyte‐contractile defects
and apoptosis partially due to lack of PKRŗ signaling in cardiomyocytes. [řŚ]
In endothelial cells (ECs), PKRŗ activates “kt and M“PK to promote proliferation, migration
and angiogenesis. In agreement with the in vitro indings, the speciic loss of PKRŗ from mouse
ECs resulted in defective angiogenesis, leading to necrosis/apoptosis in the surrounding
tissues in several organs, including the heart and kidneys [Řř].
There was signiicantly less capillary formation in adult PKRŗec‐/‐ hearts. The posterior walls
of PKRŗec‐/‐ hearts were thinner, which was due to the loss of capillary formation and a high
level of apoptosis [Řř]. The remaining viable heart muscle is subject to greater biomechanical
stress, triggering hypertrophy [Řř]. Shortening fractions (indicators of left ventricular contrac‐
tility) were progressively reduced in mutant mice. PKRŗec‐/‐ hearts displayed EC deregulation,
capillary refraction, apoptosis, ibrosis and ectopic lipid deposition, abnormal insulin signaling
in hearts resulting in impaired diastolic function.
The ECs of hearts exhibited severely decreased FICT‐insulin uptake, indicating defective
transcapillary transport of insulin in the vascular wall of these mice. Isolated ECs from the
mutant cardiac and renal tissues exhibited very litle insulin uptake, conirming that the loss
of PKRŗ from EC decreased insulin transport [Řř]. Overexpressing PKRŗ in these ECs pro‐
moted luorescein isothiocyanate (FITC)‐insulin passage. Indeed, the primary defect linking
insulin resistance and endothelial dysfunction is believed to be nitric oxide deiciency of
endothelial origin [řś]. In agreement, insulin uptake and insulin‐mediated eNOS activation
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were impaired in all mutant ECs. Similarly, altered eNOS activation and low insulin action
have recently been demonstrated in the endothelium of patients with diabetes mellitus [řŜ].
Thus, impaired insulin delivery to ECs may lead to defective NOS and eNOS activation in
PKRŗec‐/‐ aortas, consequently impairing endothelium‐dependent relaxation. These data
highlight the role of PKRŗ as a positive regulator of insulin uptake [řŝ].
PKRŗ signaling also contributes to heart development. In developing heart, PKRŗ regulates
epicardial‐mesenchymal transition (EMT) to form epicardial‐derived progenitor cell (EPDC)
[řŞ]. Genetic ablation of PKRŗ in epicardium leads to ventricular hypoplasia and septal defects
during embryogenesis. Impaired vasculogenesis in these mice is due to impaired EPDC
proliferation as well as a defective EPDC diferentiation into endothelial and smooth muscle
cell type. PKRŗ in EPDCS activates “kt signaling, changes cell morphology, actin cytoskeleton
remodeling and EMT gene expression proile. Epicardial‐PKRŗ contributes to cardiomyocyte,
proliferation and rhythmicity in a paracrine pathway.
Ř.ś. Prokineticin in renal development and function
Global PKRŗ‐knockout mice have peripheral obesity accompanied by a diabetes‐like syn‐
drome at the late ages (řŜ weeks old) [ŝ], mainly due to endothelial dysfunction and impaired
adipose tissue functions [řŝ]. These mice also exhibited cardiomegaly, severe interstitial
ibrosis and cardiac dysfunction under the stress conditions. These mice also displayed
impaired renal tubular dilation, reduced glomerular capillaries, urinary phosphate excretion
and proteinuria [řŚ].
Similarly, endothelial‐speciic PKRŗ‐knockout mice (PKRŗec‐/‐) also displayed dilatation of
”owman's spaces in most glomeruli, a compact glomerulus, ibrosis and enlarged tubular
structures with a swollen necrotic nucleus, abnormal mitochondria and aberrant organization
of podocytes. “bnormal tubular function with higher levels of absolute renal phosphate (Pi)
excretion in the PKRŗec‐/‐ mice is due to lower levels of sodium‐calcium and sodium phosphate
exchanger. The morphological changes in the PKRŗec‐/‐ kidneys were associated with higher
levels of apoptosis and impaired insulin signaling and lipid accumulation. Mutant mice
displayed high levels of creatinine clearance and proteinuria. [řŚ] Endothelial dysfunction
resulted from loss of PKRŗ signaling partially underlies the pathological features of heart and
kidney.
PKRŗ signaling in kidney is essential for nephron development during embryogenesis [řŞ].
Recently, it has been shown that mutant mice with targeted PKRŗ gene disruptions in nephron
progenitors exhibited partial embryonic and postnatal lethality due to hypoplastic kidneys
with premature glomeruli and necrotic nephrons. Kidney developmental defects in these mice
are manifested in the adult stage as renal atrophy with glomerular defects, nephropathy and
uremia. Thus, PKRŗ is necessary for renal mesenchymal‐epithelial transition (MET) that is
involved in the formation of renal progenitors, regulating glomerulogenesis toward forming
nephrons during kidney development. Indeed, PKRŗ through NF“Tcř modiies MET proc‐
essing to the development of nephron.
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ř. Conclusion
PKRŗ signaling has various beneicial efects, e.g., central regulation of appetite, the sup‐
pression of adipocyte mass and insulin‐sensitizing efects on skeletal muscle and other
tissues, cardiac regenerative efects and regulation of kidney function. This has atracted
considerable interest in the possible use of this receptor as a target for treatments combating
obesity, diabetes and cardiovascular diseases. Intracardiac PKRŗ gene transfer improved
survival rate and heart functions after myocardial infarction [řř]. Since PKRŘ has been found
to contribute to vascular leakage and hypertrophic cardiomyopathy [řş], several laboratories
are focused on the discovery of PKRŗ agonist. Recently, PKRŗ non‐peptide agonist has been
identiied [ŚŖ]. PKRŗ agonist prevents cardiac lesion formation and improved cardiac
function after myocardial infarction in mice, promoting proliferation of cardiac progenitor
cells and neovasculogenesis. PKRŗ agonist in treatment strategies of metabolic disease
remains to be studied.
How prokineticin‐Ř contributes to the “T remodeling [Śŗ], how it modulates the interaction
between the adipocytes, macrophages and endothelial cells to regulate “T expansion [ŚŘ]
remains also to be determined. Circulating prokineticin levels in obese, diabetic and heart
failure patients remain to be explored.
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